Summary: Both in‰ux and eOEux transporters are thought to be involved in the intestinal absorption of fexofenadine. The present study examined the in‰ux transporter-mediated intestinal absorption of fexofenadine in rats, focusing on the role of rat oatp3 (Oatp1a5). The intestinal permeability of fexofenadine was evaluated by means of the Ussing chamber method in the presence of a P-glycoprotein inhibitor to block eOEux transport. The permeability of fexofenadine from the mucosal to the serosal side was higher than that from the serosal side to the mucosal side. Transport of fexofenadine was saturable, and was signiˆcantly decreased by an organic anion transporting polypeptide (oatp) inhibitor. Furthermore, uptake of fexofenadine by Xenopus oocytes expressing rat oatp3 was signiˆcantly greater than that by water-injected oocytes, and the a‹nity of oatp3 for fexofenadine (Km) was about 60 mM, which is comparable with the value obtained by the Ussing chamber method using rat intestinal tissues. These results indicate that oatp3 plays a role as an in‰ux transporter in the intestinal absorption of fexofenadine in rats.
Introduction
Fexofenadine is a hydrophilic (log P＝0.30), nonsedating histamine H1-receptor antagonist, which is active after oral administration (product information, Aventis Pharmaceuticals, Inc.). Coadministration of erythromycin (500 mg three times a day) or ketoconazole (400 mg once daily) with fexofenadine results in a substantial increase in the steady-state plasma concentration of fexofenadine and its plasma AUC by 109z or 164z, respectively (product information, Aventis Pharmaceuticals, Inc.). This observation may be explained by the involvement of eOEux transport via P-glycoprotein in the fexofenadine absorption process. [1] [2] [3] It is also known that the intestinal absorption of fexofenadine in humans is decreased in the presence of fruit juices that may contain intestinal in‰ux transporter inhibitors. [4] [5] [6] In those studies, an increase of the concentration of the fruit juices led to a decreased bioavailability of fexofenadine in humans, 4) and a normal concentration of fruit juice at high volume also led to a decrease of the oral bioavailability of fexofenadine in humans and rats. 6, 7) These results imply a key role of in‰ux transporter(s) in fexofenadine absorption. Fexofenadine is a substrate of organic anion transporting polypeptides (OATP W oatps), such as human OATP1A2, OATP2B1, and OATP1B3 and rat oatp1 (1a1), oatp2 (1a4), and oatp3 (1a5). 2, 4, 9) Recently, we reported that OATP2B1 is localized at the apical membrane of human small intestinal epithelial cells 9) and we showed that fexofenadine was transported by OATP2B1 in transfected cells. 10) However, oatp3 is expressed at the apical membrane of rat small intestine 11) and fexofenadine is a substrate of oatp3. 4) The decrease of fexofenadine absorption in humans upon coadministration with fruit juices, mentioned above, may be explained by the inhibition of OATP-mediated in‰ux by components of the fruit juices. Very recently, it was also reported that fruit juices reduced the transport of estrone-3-sulfate mediated by OATP2B1 in in vitro experiments. 12) Accordingly, it is possible that OATP1B2 or other similar transporters are involved in the in‰ux process of fexofenadine and their function is inhibited by constituents of fruit juices. However, there is a species diŠerence in OATP W oatp transporters and the participation of OATP2B1 in human intestinal absorption is di‹cult to clarify in vivo. Thus, animal experiments using both in vitro and in vivo methods should be useful to clarify the mechanism of transporter-mediated intestinal absorption of fexofenadine. The counterpart of OATP2B1 in rats is not clear, but oatp3 in rats is expressed at the apical membrane of rat small intestinal epithelial cells 11) and can transport fexofenadine in in vitro-transfected cells, 4) though the transport characteristics of oatp3-mediated transport of fexofenadine have not been examined in detail. Accordingly, in the present study, we investigated the in‰ux transporter-mediated intestinal absorption of fexofenadine in rats using rat intestinal tissues and compared the transport characteristics with those of oatp3 to evaluate the contribution of OATP W oatp transporters to the intestinal absorption of fexofenadine. Transport experiments by the Ussing-type chamber method: Rat intestinal tissue sheets were prepared as described previously. 13) Male Wistar rats (8 or 9 weeks, Saitama Experimental Animals Supply Co., Ltd. (Saitama, Japan)) were anesthetized with urethane and a segment of jejunum was removed. The tissue was rapidly stripped of serosal muscle layers, and mounted vertically in an Ussing-type chamber that provided an exposed area of 0.5 cm 2 . The volume of bathing solution on each side was 4.5 mL, and the temperature was maintained at 379 C. The transport medium consisted of 128 mM NaCl, 5.1 mM KCl, 1.4 mM CaCl2, 1.3 mM MgSO4, 21 mM NaHCO3, 1.3 mM KH2PO4, 10 mM NaH 2 PO 4 , and 5 mM glucose at pH 7.4 and was gassed with 100z O2 before and during the transport experiments. In the inhibition studies, the inhibitors, ketoconazole (50 mM) and W or estrone-3-sulfate (1 mM) were added to both the mucosal and serosal chambers. Glass test tubes were used for the experiments to avoid adsorption of fexofenadine on the container. For quantitation of fexofenadine, high-performance liquid chromatography (HPLC) was used as described below. For estimation of paracellular permeability, [ 14 C]inulin was used. Radioactivity was measured with a liquid scintillation counter (LSC-5100, Aloka, Tokyo) using Cleasol-1 as a liquid scintillation ‰uid (Nakalai Tesque, Kyoto, Japan).
Materials and Methods

Materials
Transport was estimated in terms of permeation Transport experiments in Xenopus oocytes expressing oatp3: The oatp3 cDNA was PCR-ampliˆed using rat intestinal cDNA as a template, with upstream primer 5?-ttcaagcttatgggagaaacagagaaaag-3? and downstream primer 5?-agaattcatgatcttgcacagggcagtag-3?, based on the reported oatp3 cDNA sequence 11) (GeneBank accession #AF083469). A major 2.0-kilobase polymerase chain reaction product was digested with Hind III and EcoR I, and ligated into the expression gene vector pGEMHE, which was kindly provided by Dr. ER Liman. 14) Complementary RNA (cRNA) of oatp3 was prepared by in vitro transcription using T7 RNA polymerase in the presence of ribonuclease inhibitor and RNA cap analog using a mMESSAGEm-MACHINE kit (Ambion, Austin, TX). Uptake experiments were conducted as described previously. 15) Brie‰y, for standard experiments, defolliculated oocytes were injected with 50 nL of water containing 50 ng of cRNA, cultured for 3 days at 189 C in modiˆed Barth's solution (96 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.82 mM MgSO4, 0.33 mM Ca(NO3)2, 0.41 mM CaCl2 and 10 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES) adjusted to pH 7.4) and used for uptake experiments. Uptake was initiated by incubating the oocytes at room temperature in modiˆed Barth's solution containing a test compound. At appropriate times, the oocytes were washed with ice-cold modiˆed Barth's solution to terminate the uptake. For quantitation of test compounds, the oocytes were solubilized in 5z sodium dodecyl sulfate solution in the case of radioactive compound ([ 3 H]estrone-3-sulfate). For nonradioactive compounds, the oocytes were homogenized by sonicating in 0.1 mL of modiˆed Barth's solution, mixed with an equal volume of methanol, and centrifuged at 7000 rpm for 10 min. The resultant supernatant was analyzed by HPLC as described below. For the assay of background uptake by the oocytes, the same volume of water without any cRNA was injected into oocytes, which were cultured in modiˆed Barth's solution, and the uptake was quantitated in the same manner as described above. The uptakes were expressed as the cell-to-medium ratio calculated by dividing the cellular uptake amount by the concentration of test compound in the uptake medium.
Analytical methods: Fexofenadine was quantiˆed by means of HPLC using a reversed-phase analytical 
Results
EŠect of P-glycoprotein inhibitor on permeability of fexofenadine: It was reported that P-glycoprotein is involved in eOEux transport of fexofenadine in the intestine.
2) Because the purpose of the present study is to evaluate the in‰ux transport process of fexofenadine, an inhibitor of P-glycoprotein was used in order to highlight the in‰ux process. Since 50 mM ketoconazole was shown to inhibit P-glycoprotein in the same intestinal chamber method. 16) We also used 50 mM ketoconazole as the P-glycoprotein inhibitor. The mucosal-to-serosal permeability of fexofenadine was signiˆcantly increased from 2.24±0.11 to 3.49±0.19× 10 -6 cm W sec in the presence of ketoconazole, in the upper region of the small intestine ( Table 1 ). In the lower region of the small intestine, a similar increase of the permeability from 1.75±0.07 to 4.56±0.26×10 -6 cm W sec was observed ( Table 1) .
Since the increase of permeability in the presence of ketoconazole might involve the paracellular pathway, the paracellular permeability in the presence and absence of ketoconazole was evaluated by measuring the apparent permeability of [ 14 C]inulin, a paracellular marker. As shown in Table 1 , ketoconazole did not alter the permeability of inulin ( Table 1) . Subsequent experiments using the chamber method were performed in the presence of 50 mM ketoconazole.
Permeability of fexofenadine across the intestinal tissues: To examine whether an in‰ux transporter is associated with apical uptake of fexofenadine, the permeability of fexofenadine was measured in the mucosal-to-serosal and serosal-to-mucosal directions in the presence of ketoconazole. The permeability of fexofenadine in the mucosal-to-serosal direction (3.49± 0.19×10 -6 cm W sec) was signiˆcantly higher than that in the serosal-to-mucosal direction (2.82±0.15×10 -6 cm W sec), as shown in Fig. 1 . To characterize further the Fexofenadine transport from the mucosal side to the serosal side was measured at concentrations of 50 to 500 mM in the presence of ketoconazole (50 mM). The experimental solution was adjusted to pH 7.4 and the temperature was maintained at 379 C. Each point represents the mean±S.E.M. (n＝4-12). in‰ux transporter, the concentration dependence of the permeability of fexofenadine was examined in the concentration range of 50-500 mM. As shown in Fig. 2 , the permeability decreased with increasing concentration from 50 to 100 mM, but no further decrease in permeability was observed at higher concentrations. Although we could not evaluate the permeability at lower concentrations to obtain kinetic parameters, because of the detection limit of fexofenadine, the results apparently suggested that Km of fexofenadine is of the order of ten mM in rat small intestine (Fig. 2) .
EŠect of oatp inhibitor on transport of fexofenadine: We investigated the involvement of oatp3 in intestinal absorption of fexofenadine, because oatp3 transports fexofenadine and is expressed at the apical membrane of rat small intestine. 4, 11) First of all, we examined the selective expression of oatp3 in rat small intestinal tissues. RT-PCR was used to investigate the expression of oatps in the rat small intestine and liver. mRNA expression of oatp1, 2, and 4 was observed in rat liver, but not in rat small intestine. In contrast, oatp3 was clearly detected in small intestine, but it was not detected in liver (data not shown). Then we examined the inhibitory eŠect of an oatp substrate on the transport of fexofenadine across the rat small intestinal tissues. Since estrone-3-sulfate is a good substrate of various OATPs W oatps, 17) it was used. The permeability of fexofenadine in the mucosal-to-serosal direction was signiˆcantly decreased in both the upper and lower regions of small intestine in the presence of 1 mM estrone-3-sulfate ( Table 1) .
Transport characteristics of oatp3 for fexofenadine: Involvement of oatp3 in the transport of fexofenadine in small intestine was further assessed by measuring the eŠect of increasing concentrations of fexofenadine on the transport of [
3 H]estrone-3-sulfate by oatp3 expressed in Xenopus oocytes. As shown in Fig. 3 , the evaluated 50z inhibitory concentration of fexofenadine (IC50) was 25.4±4.0 mM. In addition, the concentration dependence of fexofenadine transport by oatp3 was examined by using oatp3-expressing Xenopus oocytes. The uptake of fexofenadine was saturable with Km and Vmax values of 59.1±18.8 mM and 57.8±4.7 pmol W oocyte in 120 min (Fig. 4) .
Discussion
The purpose of the present study was to examine the involvement of in‰ux transporter(s) in the intestinal absorption of fexofenadine in rats. Several previous studies have suggested that OATP-like transporters could be involved in the absorption of fexofenadine. 2, 4, 9) It was shown that human OATP2B1 (OATP-B) transports various organic anions, including fexofenadine, in a pH dependent manner in our study using OATP2B1-transfected cells. 10) Furthermore, intestinal absorption of fexofenadine is reduced by coadministration of fruit juices, [4] [5] [6] components of which reduce the transport activity of OATP2B1 in transfected cells. 12) Although several rat oatps and human OATP1A2 (OATP-A) transport fexofenadine, there is nevertheless a report that an in‰ux transporter is apparently not involved in humans. 18) Thus, the situation remains unclear. Since direct experimental demonstration that OATP2B1 or some other OATP transporter molecule is involved in the absorption of fexofenadine in humans is di‹cult, animal experiments would be an alternative approach. Due to the lack of expression in rat small intestinal tissues, oatp1, 2, and 4 are excluded as the intestinal transporter for fexofenadine. However, oatp3 was detected in small intestinal tissues, which is consistent with the previous observation by Walter et al..
11)
Although OATP2B1 shows higher amino acid homology to the rat moat1 than to oatp3, oatp3 is the only rat oatp transporter known to be expressed at the apical membrane of small intestinal epithelial cells at present. So, to demonstrate the oatp-mediated absorption of fexofenadine in rats, it is necessary to compare the transport of fexofenadine in rat intestinal tissues and that by the rat oatp molecule expressed in the rat intestinal tissues. Another complicating factor is the involvement of the eOEux transporter P-glycoprotein in intestinal transport of fexofenadine. 2, 19) To avoid the eŠect of P-glycoprotein-mediated eOEux, we examined the intestinal absorption of fexofenadine in the presence of ketoconazole as an inhibitor of P-glycoprotein. Accordingly, in the present study we examined the transport of fexofenadine across isolated rat intestinal tissues in the presence of ketoconazole to block P-glycoprotein, and in cells transfected with rat intestinal oatp3, in order to demonstrate that fexofenadine is absorbed via the oatp transporter in rat intestine.
First of all, we measured the permeability of fexofenadine across intestinal tissues mounted in an Ussing type chamber in the presence and absence of ketoconazole as a P-glycoprotein inhibitor. The concentration of ketoconazole was set at 50 mM, since it has been reported that eOEux transport of verapamil, a substrate of P-glycoprotein, was inhibited by 50 mM ketoconazole in the same rat intestinal chamber method. 16) As expected, the mucosal-to-serosal permeability of fexofenadine was increased in the presence of ketoconazole in both the upper and lower regions of the small intestine, with a greater ratio of increase in the lower region of the small intestine ( Table 1) . Since P-glycoprotein expression is greater in the lower region of small intestine than in the upper region, 20, 21) the above observation can be explained by the inhibition of P-glycoprotein-mediated eOEux of fexofenadine by ketoconazole. Therefore, ketoconazole can be used to highlight the in‰ux transport of fexofenadine across the small intestine.
The higher mucosal-to-serosal permeability of fexofenadine in the presence of ketoconazole (Fig. 1) , the saturability of absorptive permeability (Fig. 2) , and the signiˆcant reduction of fexofenadine transport in the presence of estrone-3-sulfate (Table 1) all strongly suggest that an in‰ux transporter, such as oatp, is involved. We used estrone-3-sulfate at 1 mM to inhibit oatps, since estrone-3-sulfate exhibited Km values of 4.5-11, 11, 268 and 37 mM for oatp1, 2, 3, and 4, respectively. 17) In the inhibition study by estrone-3-sulfate, the decrements were comparable for upper and lower regions, showing 1.50 and 1.34 ×10 -6 cm W sec, respectively. Therefore, it was considered that there is no regional diŠerence in transport activity of in‰ux transporter, which can be inhibited by estrone-3-sulfate, between upper and lower regions. Since there is the report that oatp3 mRNA was expressed at similar levels down the length of the small intestine, 11) the present observation is consistent with the lack of regional diŠerence of oatp3 expression level. On the other hand, there was regional diŠerence in the permeability in the presence of both of ketoconazole and estrone-3-sulfate between upper and lower regions. At lower region, the permeability in the presence of those two inhibitors (3.22×10 -6 cm W sec) was signiˆcantly higher than that in the absence of them (1.75×10 -6 cm W sec), while those permeabilities at upper region were comparable (2.24 and 2.35×10 -6 cm W sec). This regional diŠerence may be explained by the higher expression of eOEux transporter P-gp 20, 21) and W or the contribution of unknown in‰ux transporter that cannot be inhibited by estrone-3-sulfate at lower part of small intestine. The mucosal-toserosal permeability was saturated at about 0.1 mM (Fig. 2) . Because of the detection limit of the quantitation, we were unable to obtain an exact Km value, but this observation suggested that fexofenadine has a Km value lower than 0.1 mM. The a‹nity of fexofenadine for the intestinal in‰ux transporter is close to the Km values of fexofenadine uptake by oatp1 (32 mM) and oatp2 (6.0 mM) expressed in HeLa cells (2) and the Km value of oatp3 obtained in the present study (59 mM) (Fig. 4) . Furthermore, the IC50 of fexofenadine on oatp3-mediated transport of estrone-3-sulfate was similar to the Km of fexofenadine transport by rat oatp3. All of these observations are consistent with the hypothesis that rat oatp3 is involved in the intestinal absorption of fexofenadine in rats.
In conclusion, by evaluating the intestinal transport of fexofenadine in the rat intestinal tissues in the presence of a P-glycoprotein inhibitor, we could clearly observe saturable absorptive transport of fexofenadine. Furthermore, the a‹nity of fexofenadine transport across rat intestinal tissues was comparable with the Km value of fexofenadine for rat oatp3. These results provide strong evidence that fexofenadine is absorbed via oatp3 in rats. Since OATP1A2 was recently reported to transport fexofenadine and to be expressed in human small intestinal tissues, 2, 22) like OATP2B1, further studies on the mechanism of human intestinal absorption of fexofenadine, based on these animal experimental observations, seem to be desirable. 
